Crossmark

Mirvetuximab soravtansine in platinum-resistant ovarian cancer: from biological rationale to clinical impact and future directions

Published Online: 2026-06-13

Published Print: 2026-08

Authors

Mabuchi, Seiji https://orcid.org/0000-0003-1803-1166
Kusakabe, Ai

Sasano, Tomoyuki
License Information

Text and Data Mining valid from 2026-06-13

Version of Record valid from 2026-06-13
More Information

Article History

Received: 27 April 2026

Accepted: 3 June 2026

First Online: 13 June 2026

Declarations

Conflict of interest: The authors declare no conflicts of interest.

Document is current